Pnu anthracycline derivatives and methods of use thereof

A compound having a structural Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is H or C1-6 alkyl;
• R2 is selected from C1-C6 hydroxyalkyl, 5 to 11-membered bridged bicyclic heterocycloalkyl, 5 to 11-membered fused bicyclic heterocycloalkyl, C1-C6 aminoalkyl, —(C1-C6 alkylene)-NR3C(O)—(C1-C6 aminoalkyl), —(C1-C6 alkylene)-NHC(O)NHNH2, —(C1-C6 alkylene)-NR3, —(C1-C6 alkylene)-N(R3)—(C1-C6 alkylene)-N(R3)—NHC(O)—(C1-C6 aminoalkyl), —(C1-C6 haloalkylene)-NR3, —(C1-C6 alkylene)n-(3 to 7-membered monocyclic heterocycloalkyl), —(C1-C6 alkylene)-NR3C(O)-(3 to 7-membered monocyclic heterocycloalkyl), —(C1-C6 alkylene)-NR3C(O)—(C3-C7 monocyclic cycloalkyl), —(C1-C6 alkylene)n-(C5-C11 fused bicyclic cycloalkyl), —(C1-C6 alkylene)n-(C5-C11 bridged bicyclic cycloalkyl), —(C1-C6 alkylene)n-(C3-C7 monocyclic cycloalkyl), —(C1-C6 alkylene)n-(C6-C10 aryl), —(C1-C6 alkylene)n-(5 or 6-membered monocyclic heteroaryl), and 5-11 membered spirocyclic heterocycloalkyl, wherein said 3 to 7-membered monocyclic heterocycloalkyl group, said 5 to 10-membered fused bicyclic heterocycloalkyl group, said 5 to 10 membered bridged bicyclic heterocycloalkyl group, said C3-C7 monocyclic cycloalkyl group, said C6-C10 aryl group, said 5 or 6-membered monocyclic heteroaryl group, said C5-C11 bicyclic cycloalkyl group, and said 5-11 membered spirocyclic heterocycloalkyl group can each be optionally and independently substituted with one or more RA groups, and wherein said 3 to 7-membered monocyclic heterocycloalkyl group can have one or more ring carbon atoms substituted with an oxo group;
• alternatively, R1 and R2, taken together with the common nitrogen atom to which they are each attached, join to form:
• (i) a 3 to 7-membered monocyclic heterocycloalkyl group, (ii) a 5 to 11-membered bridged bicyclic heterocycloalkyl group, (iii) a 5 to 11-membered fused bicyclic heterocycloalkyl group, or (iv) a 5 to 11-membered spirocyclic heterocycloalkyl group, wherein said 3 to 7-membered monocyclic heterocycloalkyl group, said 5 to 11-membered bicyclic heterocycloalkyl group, said 5 to 11-membered fused heterocycloalkyl group, and said 5 to 11-membered spirocyclic heterocycloalkyl group can each be optionally and independently substituted with one or more RB groups;
• each occurrence of R3 is independently H or C1-6 alkyl;
• each occurrence of RA is independently selected from C1-6 alkyl, halo, —CN, —OR3, —(C1-C6 alkylene)n-N(R3)2, C1-C6 aminoalkyl, —(C1-C6 alkylene)-NHC(O)—(C1-C6 aminoalkyl), —O—(C1-6 alkyl), —NHC(O)CH2OH, and —(C1-C6 alkylene)-(3 to 7-membered monocyclic heterocycloalkyl), wherein a 3 to 7-membered monocyclic heterocycloalkyl group can be optionally and independently substituted with one or more Rc groups;
• each occurrence of RB is independently selected from C1-6 alkyl, halo, —CN, —OR3, —N(R3)2, C1-C6 aminoalkyl, —(C1-C6 alkylene)-NHC(O)—(C1-C6 aminoalkyl), —O—(C1-6 alkyl), —NHC(O)CH2OH, and —(C1-C6 alkylene)-(3 to 7-membered monocyclic heterocycloalkyl), wherein a 3 to 7-membered monocyclic heterocycloalkyl group can be optionally and independently substituted with one or more Rc groups;
• each occurrence of Rc is independently selected from C1-6 alkyl, halo, —CN, —OR3, —N(R3)2, C1-C6 aminoalkyl, —O—(C1-6 alkyl), —NHC(O)—(C1-C6 aminoalkyl), —(C1-C6 alkylene)-NHC(O)—(C1-C6 aminoalkyl), C1-6 alkyl, halo, —CN, —OR3, —N(R3)2, —O—(C1-6 alkyl), and —NHC(O)CH2OH;
• and
• each occurrence of n is independently 0 or 1.